ArticleAngewandte Chemie (International ed. in English)2015
A Fluorescent Adenosine Analogue as a Substrate for an A-to-I RNA Editing Enzyme.
Article in Angewandte Chemie (International ed. in English), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Site-specific RNA modificationRSC chemical biology · 2024Article
- Isomorphic Fluorescent Nucleosides.Accounts of chemical research · 2024Article
- Chemical Profiling of A-to-I RNA Editing Using a Click-Compatible Phenylacrylamide.Chemistry (Weinheim an der Bergstrasse, Germany) · 2020Article
- Probing of Nucleic Acid Structures, Dynamics, and Interactions With Environment-Sensitive Fluorescent Labels.Frontiers in chemistry · 2020Review
- NAD Analogs in Aid of Chemical Biology and Medicinal Chemistry.Molecules (Basel, Switzerland) · 2019Review
- Identification of Adenosine-to-Inosine RNA Editing with Acrylonitrile Reagents.Organic letters · 2019Article
- Emissive Synthetic Cofactors: A Highly Responsive NADChemistry (Weinheim an der Bergstrasse, Germany) · 2019Article
- Emissive Synthetic Cofactors: Enzymatic Interconversions ofAngewandte Chemie (International ed. in English) · 2018Article
- Fluorescent nucleobases as tools for studying DNA and RNA.Nature chemistry · 2017Review
- Expanding a fluorescent RNA alphabet: synthesis, photophysics and utility of isothiazole-derived purine nucleoside surrogates.Chemical science · 2017Article
- Polymerase-Mediated Site-Specific Incorporation of a Synthetic Fluorescent Isomorphic G Surrogate into RNA.Angewandte Chemie (International ed. in English) · 2017Article
- Chemoenzymatic synthesis and utilization of a SAM analog with an isomorphic nucleobase.Organic & biomolecular chemistry · 2016Article
- Chemical Mutagenesis of an Emissive RNA Alphabet.Journal of the American Chemical Society · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Adenosine to inosine RNA editing catalyzed by ADAR enzymes is common in humans, and altered editing is associated with disease. Experiments using substrate RNAs with adenosine analogues at editing sites are useful for defining features of the ADAR reaction mechanism. The reactivity of ADAR2 was evaluated with RNA containing the emissive adenosine analogue thieno[3,4-d]-6-aminopyrimidine ((th)A). This nucleoside was incorporated into a mimic of the glutamate receptor B (GluR B) mRNA R/G editing site. We found that (th)A is recognized by AMV reverse transcriptase as A, and is deaminated rapidly by human ADAR2 to give (th)I. Importantly, ADAR reaction progress can be monitored by following the deamination-induced change in fluorescence of the (th)A-modified RNA. The observed high (th)A reactivity adds to our understanding of the structural features that are necessary for an efficient hADAR2 reaction. Furthermore, the new fluorescent assay is expected to accelerate mechanistic studies of ADARs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.